Abstract: We present a case of diarrhea secondary to biopsy-proven adenovirus (ADV) infection after autologous peripheral hematopoietic stem cell transplant for multiple myeloma. The patient had a negative plasma polymerase chain reaction for ADVand a dramatic clinical response to low-dose cidofovir. To our knowledge, this is the ¢rst report in an adult hematopoietic stem cell recipient of the use of low-dose cidofovir to treat proven ADVgastrointestinal infection.
Adenovirus (ADV) is a common cause of self-limited upper respiratory, conjunctival, or gastrointestinal (GI) disease in immunocompetent individuals, but has emerged as a pathogen causing signi¢cant morbidity in transplant patients. In hematopoietic stem cell transplant (HSCT) recipients, the incidence of ADV infection has been reported to be anywhere between 3% and 47% (1^15). Asymptomatic infection due to ADV manifests as GI or urinary shedding and usually precedes symptomatic disease (13, 16, 17 ) . Both urinary and GI tracts are the commonly observed sites of adenoviral disease in HSCT recipients (5^7, 9^13). Current standard treatment for systemic ADV disease, based on small studies, is high-dose cidofovir (5 mg/kg q 1^2 weeks) with probenicid (17^22). Low-dose cidofovir (LDC) (i.e., 1 mg/kg 3 times a week) has been tried for ADV-associated hemorrhagic cystitis and non-urinary tract disease in children (9, 23, 24) , and disseminated disease and hemorrhagic cystitis in adult allogeneic HSCT recipients (15) . However, the e⁄cacy of LDC therapy for ADV-associated GI disease following HSCT is not known. Because of the nephrotoxicity of cidofovir, LDC may be an attractive option for some patients.We report a case of diarrhea due to ADVafter autologous HSCT that responded well to LDC. The patient had a negative plasma polymerase chain reaction (PCR) for ADV but had proven ADV-induced diarrhea based on clinical presentation and positive GI tract biopsy.
Case presentation
A 66 -year-old male was diagnosed in 1/06 with stage IIIA immune globulin G (IgG) k-multiple myeloma. His disease was initially diagnosed following a chest computed tomography (CT) scan that was done for evaluation of chest pain, and revealed a left chest wall mass that on biopsy was a plasmacytoma. Subsequently, he had a bone marrow biopsy, which showed 51% plasma cells consistent with multiple myeloma. He received approximately a year of dexamethasone and thalidomide and was in near complete remission before his transplant. He had low-level persistence of myeloma cells in his bone marrow 2 weeks before his transplant. His serum calcium (peak 11 mg/dL; normal value [NV]: 8.6^10.3 mg/dL) and IgG protein (peak: 6 g/dL; NV: 0.56^1.25 g/dL) had normalized. His b-2 microglobulin remained elevated at 2.2^3.0 mg/dL (NV: 0^2 mg/dL). Before he developed multiple myeloma, the patient also had a history of well-controlled atrial ¢brillation, hypothyroidism, and depression.
The patient received melphalan (200 mg/m 2 ) 2 days before transplant. He was infused with the following autologous stem cell doses: 2.3 Â 10 6 and 0.86 Â 10 6 CD34 1 cells/kg on days 1 and 2, respectively. Post transplant, he was given low-dose dexamethasone at 4 mg b.i.d. for 4 days. Two days after HSCT, he had intractable nausea and vomiting, resulting in dehydration and multiple electrolyte de¢ciencies that required him to be on total parenteral nutrition. He also developed a rapid ventricular response from his atrial ¢brillation, which was controlled with metoprolol and digoxin. He received cefepime after he developed a low-grade fever. This was discontinued 4 days later after chest radiograph, blood, and urine cultures were negative. His nadir absolute neutrophil count of 600 cells/mm 3 lasted only for a day, with most values above 1000 cells/ mm 3 . F|ve days post transplant, he developed large volume (maximum $ 4^6 L/day), watery diarrhea with a peak frequency of 15^20 bowel movements/day. He did not respond to octreotide or loperamide. The following studies were negative: stool bacterial culture, stool examination for ova and parasites, stool rotavirus antigen by enzyme immunoassay (EIA), shiga-like toxin assay by EIA, human herpesvirus 6 and cytomegalovirus (CMV) plasma PCR, and Clostridium di⁄cile A and B toxin assay (Â 3). His absolute lymphocyte count (ALC) remained o400 cells/mm 3 for at least 2 weeks while he was having diarrhea (F|g. 1). He had a positive stool ADV antigen by EIA on day 6 of illness. His ADV serum antibody was negative. Stool examination for white blood cells, stool viral culture, and ADV serotyping were not performed. His plasma ADV PCR was checked twice and was negative. He had a CT scan of his abdomen and pelvis on day 7 of his diarrhea, which showed di¡use small bowel thickening (F|g. 2). A colonoscopy and esophagogastroduodenoscopy on day 10 of his illness showed the following: esophagitis (distal third); di¡use, moderate mucosal abnormality characterized by congestion and decreased vascular pattern in the stomach; moderate hemorrhagic appearance in the cardia; di¡use nodular mucosa in the duodenum; and congestion, granular, and vascular-pattern-decreased mucosa in his rectosigmoid and descending colon. The infectious disease division was consulted on day 10 and LDC (1 mg/kg 3 times a week) was started. Probenecid was not given because the patient could not tolerate anything by mouth. Adequate intravenous hydration was ensured. Renal function remained stable (baseline creatinine was 0.8 mg/dL, and after LDC creatinine was 0.6 mg/dL [NV: 0.7^1.3 mg/dL]).Two days after starting LDC, the volume of his diarrhea improved dramatically and resolved completely within 2 weeks of treatment (F|g. 1). Biopsy of his stomach (F|g. 3), duodenum, and colon revealed ADV inclusions. Immunohistochemical staining for ADV from all biopsied sites was also positive (F|g. 4). The patient was CMV IgG negative but herpes simplex virus (HSV) IgG positive, thus immunohistochemical staining for the latter virus was also done on these tissue samples and found to be negative. 
Discussion
In this report, we describe a case of ADV infection of the GI tract that responded dramatically to LDC. The case was diagnosed based on clinical presentation, stool ADV antigen, and con¢rmed by biopsy. The report also emphasizes that signi¢cant GI tract disease may be present with a negative plasma PCR even in highly immunosuppressed hosts. In HSCT recipients, ADV is commonly associated with upper and/or lower respiratory tract infection, GI disease, hepatitis, or hemorrhagic cystitis (25) . Diarrhea caused by ADV may be di⁄cult to distinguish from other causes of diarrhea such as Clostridium di⁄cile infection, CMV colitis, chemotherapy, and graft-versus-host disease (GVHD) (26, 27 ) . In its most severe form, patients can develop hemorrhagic colitis. The serotypes most commonly detected in transplant recipients with diarrhea belong to subgroups B and C; these subgroups also account for the majority of clinical isolates in HSCT patients worldwide (1, 2, 26) .
ADVdisease in HSCT recipients is usually a reactivation of latent infection and is more common in children, patients with T-cell depleted or mismatched grafts, and patients with acute GVHD (25) . ADV disease is less common in recipients of autologous transplants than allogeneic transplants (2^12% in autografts vs. 12^18% in matched sibling transplant, and 16^30% in mismatched related and unrelated transplants) (28) .
Distinguishing ADVdisease from asymptomatic GI tract infection can be di⁄cult. V|ral shedding without clinical disease from the inactive or latent state of the virus in the GI tract is common (13, 16, 17 ) . Thus, in questionable cases the decision to start a nephrotoxic and expensive drug (i.e., cidofovir) is di⁄cult (25) . In our case, a positive direct immunohistochemical stain for ADV and the presence of typical nuclear inclusions (i.e., smudge cells) from GI tract biopsies (both stomach and colon) in the setting of a compatible clinical presentation (i.e., diarrhea), provided a de¢nite diagnosis of ADV disease. Our case re-emphasizes 
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the fact that de¢nite GI tract disease may not be accompanied by viremia, and that a negative plasma PCR result does not rule out invasive GI tract disease (13, 29) . In our case, we proceeded with empiric treatment with LDC before the biopsy results, because of the compatible clinical picture and lack of alternative diagnosis. We chose LDC over standard-dose cidofovir based on the theoretical advantage of decreased risk for nephrotoxicity in this patient who did not have evidence of disseminated disease. Caveats to the use of LDC are reports of breakthrough infection with certain herpesviruses (HSV and CMV) (24) and the need to continue appropriate prophylaxis.
Two case series describe the use of LDC for ADV infection (other than hemorrhagic cystitis) in HSCT recipients (9, 15) . In the ¢rst report, 8 pediatric recipients of allogeneic HSCTwere treated with at least 9 doses of LDC. Duration of treatment ranged from 3 weeks to 8 months, and only 1 patient had a signi¢cant increase in serum creatinine. Six of the 8 patients were reported to be alive and culture negative (9) . In the second report, 3 allogeneic HSCT recipients received initial therapy with at least 2 doses of LDC every other day for disseminated disease and all died of disseminated disease (15) . Other reports of LDC for the treatment of ADV-associated hemorrhagic cystitis have been published (15, 23, 24) but, because of the ability of the drug to achieve a high concentration in the urine, these reports may not be relevant to disease outside the urinary tract. To our knowledge, this is the ¢rst report to describe the use of LDC in an adult HSCT recipient with proven, localized ADV disease outside of the urinary tract.
Evaluation of response to antiviral agents and recovery from ADV disease is limited because most of the data are retrospective in nature (25) . In our report, treatment with LDC was temporally associated with clinical recovery from diarrhea. However,T-cell immunity is critical for protection against ADV infection, reactivation, and recovery (11, 30, 31) .The concept of T-cell defense against ADV infection underlies attempts to treat ADV disease with donor lymphocyte infusion or targeted adoptive immunotherapy using the patient's own ADV-speci¢c antibodies (30, 32) . Therefore, the clinical response in our patient may also be accounted for by spontaneous recovery (11, 29) , or recovery of T-cell function independent of cidofovir e¡ect. Our patient had a low ALC (o400 cells/mm 3 ) when he became symptomatic from ADV infection. He had a slow but sustainable rise in ALC that coincided with improvement of diarrhea following administration of cidofovir.
This case report, together with other small published data, suggests that use of LDC for the treatment of ADV disease might be an e⁄cacious strategy (9) . It should be noted that 1 case series demonstrated poor outcomes with LDC in patients with disseminated disease (15) . LDC may possibly be tried in the following situations: preemptive therapy to prevent disseminated disease, in mild and localized forms of the disease (i.e., non-disseminated), and possibly in patients with ADV disease and renal dysfunction. Determining the appropriate role of LDC in the treatment of adenoviral disease in this population will, however, require prospective clinical trials.
